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Abstract
Hepatitis  refers to the inflammation of the liver.  A major cause of hepatitis  is  the
hepatotropic virus, hepatitis B virus (HBV). Annually, more than 786,000 people die as a
result  of  the clinical  manifestations of  HBV infection,  which include cirrhosis  and
hepatocellular carcinoma. Sequence heterogeneity is a feature of HBV, because the viral-
encoded polymerase lacks proof-reading ability. HBV has been classified into nine
genotypes, A to I, with a putative 10th genotype, “J,” isolated from a single individual.
Comparative analysis of HBV strains from various geographic regions of the world and
from different eras can shed light on the origin, evolution, transmission and response to
anti-HBV preventative, and treatment measures. Bioinformatics tools and databases have
been used to better understand HBV mutations and how they develop, especially in
response to antiviral therapy and vaccination. Despite its small genome size of ~3.2 kb,
HBV presents several bioinformatic challenges, which include the circular genome, the
overlapping open reading frames, and the different genome lengths of the genotypes.
Thus, bioinformatics tools and databases have been developed to facilitate the study of
HBV.
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1. Introduction
Primarily, bioinformatics is the use of computational science to study biological and clinical
data using statistics, mathematics, and information theory. This field is developing and evolving;
thus, the definition cannot be precise. Moreover, the field is broad, ranging from the study of
DNA and proteins, to structural biology, drug design and comparative genomics, transcrip‐
tomics,  proteomics,  and metagenomics.  The optimization of computational technology is
paramount in order to handle, store, manage, and analyze the large volumes of data generat‐
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ed in the last decade. The data include molecular sequencing data of host and pathogen genomes
and their associations to demographic and clinical records, laboratory test results, as well as
information on treatment. Moreover, bioinformatics can aid in the investigation of virus–host
genome and environmental  interactions  and in  the  identification of  both  host  and viral
biomarkers. This analysis can lead to a better understanding of clinical manifestation of disease
and effective design of preventative and treatment measures [1].
In the first section, we describe the unique genomics and molecular biology of hepatitis B virus
(HBV). Using illustrative examples, we showed how bioinformatics analyses can facilitate the
understanding of the origin, evolution, transmission, and response to antiviral agents of HBV.
Next, we described the bioinformatics challenges posed by HBV and present the public
databases and tools currently available for the study of HBV.
2. Hepatitis B virus
2.1. Hepatitis
Hepatitis refers to the inflammation of the liver. A major cause of hepatitis is the hepatotropic
virus, HBV. HBV infection is a public health problem of worldwide importance. Globally, 2
billion people have been exposed to this virus at some stage of their lives, and 240 million are
chronic carriers of the virus [2].
This infection can lead to a spectrum of clinical consequences. In the majority of cases, the
infection is subclinical and transient, whereas in 25% of cases, it can cause self-limited acute
hepatitis and in 1% of these progress to acute liver failure. The virus can persist in 90% of
neonates and 5–10% of adults, leading to chronic infection that can progress to either chronic
hepatitis or an asymptomatic carrier state. Both of these states can ultimately develop liver
cancer or hepatocellular carcinoma (HCC), with or without the intermediate cirrhotic stage.
Annually, more than 786,000 people die as a result of these clinical manifestations of HBV
infection [3].
2.2. Prevalence
The prevalence of HBV in a community can be estimated by the proportion of the population,
who are hepatitis B surface antigen (HBsAg)-positive carriers. HBV prevalence varies widely
in the world [3]. The prevalence is low (<1%) in northern Europe, Australia, New Zealand,
Canada, and the United States of America. Northern Asia, the Indian subcontinent, parts of
Africa, Eastern and south-eastern Europe, and parts of Latin America are areas of intermediate
prevalence (1–5%). The high prevalence areas (5–20%) include East and Southeast Asia, the
Pacific Islands, and sub-Saharan Africa.
2.3. Classification and structure
HBV, the prototype member of the family Hepadnaviridae, belongs to the genus Orthohepadna‐
virus. With a diameter of 42 nm and a DNA genome of ~3.2 kilobases (kb), it is the smallest
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DNA virus infecting man. The genome is circular and partially double stranded. One DNA
strand is complete, except for a small nick (the minus strand), and the other is short and
incomplete (the plus strand). The minus strand contains four overlapping open reading frames
(ORFs; Figure 1) [4] that represent: (1) the preS/S gene that codes for the envelope proteins,
large, middle, and small HBsAgs; (2) the P gene for DNA polymerase/reverse transcriptase
(POL); (3) the X gene for the X protein, a key regulator during the natural infection process,
which has transcriptional trans-activation activity and is required to initiate and maintain HBV
replication [5]; and (4) the precore/core gene that codes for the HBcAg or core protein that forms
the capsid and for an additional protein known as HBeAg, which is not incorporated into the
virus itself but is expressed on the liver cells and secreted into the serum. Figure 2 illustrates
the structure of the hepatitis B virion.
Figure 1. The genome of hepatitis B virus (HBV). The partially double-stranded DNA (dsDNA) with the complete mi‐
nus (−) strand and the incomplete (+) strand. The four open reading frames (ORFs) are shown: precore/core (preC/C) that
encodes the e antigen (HBeAg) and core protein (HBcAg); P for polymerase (reverse transcriptase), PreS1/PreS2/S for
surface proteins [three forms of HBsAg, small (S), middle (M), and large (L)] and X for a transcriptional trans-activator
protein.
The Study of Hepatitis B Virus Using Bioinformatics
http://dx.doi.org/10.5772/63076
179
Figure 2. Schematic representation of hepatitis B virus (HBV), showing the structure of the virion, composed of a parti‐
ally double-stranded DNA genome, enclosed by a capsid, comprised of HBcAg and surrounded by a lipid envelope
containing large (L)-HBsAg, middle (M)-HBsAg, and small (S)-HBsAg. The virus also expresses two non-particulate
proteins X protein and HBeAg.
2.4. Regulatory elements of HBV
Every single nucleotide of the HBV genome is necessary for the translation of a protein and
may also be part of one of the regulatory elements of HBV, which overlap with protein
expressing regions. The regulatory elements include the S1 and S2 promoters, which overlap
both the preS region and polymerase ORFs; the preC/pregenomic promoter, which includes
the basic core promoter (BCP) and overlaps the X and preC ORF; and the X promoter. There
are two enhancers (enhancer I and enhancer II) as well as cis-acting negative regulatory
elements (URR: upper regulatory region, CURS: core upstream regulatory sequence, NRE:
negative regulatory element). These regulatory elements control transcription (reviewed in [6,
7]).
2.5. Replication of HBV
HBV and other members of the family Hepadnaviridae have an unusual replication cycle. These
DNA viruses replicate by reverse transcription of a RNA intermediate known as the prege‐
nomic RNA (pgRNA) [8]. Entry into the cell is via the sodium taurocholate cotransporting
polypeptide (NTCP), a multiple transmembrane transporter predominantly expressed in the
liver [9]. After entry, the virion is uncoated and the core particle is actively transported to the
nucleus [10], where the partially double strand relaxed circular DNA molecule is released. The
single-stranded gap is closed by the viral polymerase to yield a covalently closed circular
molecule of DNA (cccDNA) [11], which is the template for transcription by the host RNA
polymerase II [12]. The mRNAs are transported into the cytoplasm where they are translated
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into the seven viral proteins. In addition to being translated into the polymerase and the core
protein, the pgRNA is packaged into immature core particles by the process known as
encapsidation. In order to be encapsidated, the 5′ end of the pgRNA has to be folded into a
particular secondary structure known as the encapsidation signal (ε) [13].
The encapsidation signal (ε) is a bipartite stem-loop structure, consisting of an upper and lower
stem, the bulge, and an apical loop. Besides encapsidation, ε has a number of other functions
(reviewed in [13]) and references therein. It acts in template restriction so that not any piece of
RNA is encapsidated, and it also plays a role in the activation of the viral polymerase, so that
there is no indiscriminate reverse transcription. It is also involved in the initiation of reverse
transcription. The polymerase or reverse transcriptase acts as a primer of RNA-directed DNA
synthesis by the binding of the polymerase to the bulge of ε. The first three nucleotides of the
negative stand of DNA are synthesized at the bulge and are transferred to an acceptor site on
the 3’ end of the pgRNA, where DNA synthesis proceeds toward the 5′ end of the pgRNA [14],
giving rise to the immature virion. The virus matures by acquiring its glycoprotein envelope,
containing HBsAg, in the endoplasmic reticulum and is exported by vesicular transport from
the cell [15].
2.6. Genotypes and subgenotypes of HBV
Sequence heterogeneity is a feature of HBV, because the viral-encoded polymerase lacks proof-
reading ability as mentioned above [16]. Using phylogenetic analysis of the complete genome
of HBV and an intergroup divergence of greater than 7.5%, HBV has been classified into nine
genotypes, A to I [17, 18, 19], with a putative 10th genotype, “J,” isolated from a single
individual [20]. With between ~4 and ~8% intergroup nucleotide difference across the complete
genome and good bootstrap support, genotypes A–D, F, H, and I are classified further into at
least 35 subgenotypes [21]. The genotypes differ in genome length, the size of ORFs and the
proteins translated [17], as well as the development of various mutations [22]. Generally, the
genotypes, and in some cases the subgenotypes, have a distinct geographic distribution (Table
1).
GenotypeLength Differentiating
features
Subgenotypes Geographic
distribution
Serological
subtype
Transmission
route
A 3221 6-nucleotide insert
at
carboxyl end of core
gene
A1 Africa# adw2/ayw2 Horizontal:
parenteral or
sexual
A2 Europe/North America adw2
Quasi-
subgenotype
A3(A3,A4,A5)§
Africa, Haiti ayw1
A4(A6)§ Africa ayw1
adw4*
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GenotypeLength Differentiating
features
Subgenotypes Geographic
distribution
Serological
subtype
Transmission
route
B 3215 B1 Japan adw2
B2 China adw2
Quasi-
subgenotype
B3(B3,B5,B7–B9,B6(China)§
Indonesia
Philippines/China
adw2 Perinatal
B4 Vietnam/Cambodia/
France
ayw1/adw2
B5(B6)§ Eskimos/Inuits adw2
adrfntab1_3
C 3215 C1 Thailand/Myanmar/
Vietnam
adr*
Quasi-subgenotype
C2(C2,C14, undefined
sequences)§
Japan/China/Korea adr
C3 New Caledonia/
Polynesia
adr Perinatal
C4 Australian
Aborigines
ayw2/ayw3
C5 Philippines/
Indonesia
adw2
C6–C12 Indonesia/
Philippines
adr
C13–C15 Indonesia adr
C16 Indonesia ayr*
D 3182 33-nucleotide
deletion at the
amino terminus of
the preS1 region
D1 Middle East, Central
Asia
ayw2
D2 Europe/Japan/Lebanon ayw3
D3 Worldwide ayw2/ayw3
D4 Australian aborigines,
Micronesians,
Papua New Guineans,
Arctic Denes
ayw2 Horizontal:
parenteral with
intravenous
drug use being a
risk factor
D5 India ayw3/ayw2
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GenotypeLength Differentiating
features
Subgenotypes Geographic
distribution
Serological
subtype
Transmission
route
D6 Tunisia/Nigeria ayw2
ayw4*/adw3*
E 3212 3-nucleotide
deletion at the
amino terminus of
the preS1 region
– Western/Central Africa ayw4 Horizontal
F 3215 F1 Argentina/Costa
Rica/El Salvador,
Alaska
adw4
F2 Nicaragua/
Venezuela/Brazil
adw4 Horizontal
F3 Venezuela/Colombia adw4
F4 Argentina adw4
adw2*/ayw4*
¶Summarizes data compiled from Kramvis [21] and references cited therein.
§Earlier subgenotype designation.
*Rare serological subtype for that genotype.
#And in regions outside Africa where there was historical forced migration as a result of the slave trade [23].
¥Vietnamese residing in Canada [24].
Table 1. Comparison of the virological and clinical characteristics of the genotypes and subgenotypes of HBV¶.
2.7. Genotyping and subgenotyping methods
HBV genotypes, and in some cases subgenotypes and various mutations, can influence the
clinical course of disease [22] as well as response to antiviral therapy [25] and can be used to
show transmission [26] and to trace human migrations [23]. Thus, HBV genotyping is becom‐
ing increasingly relevant in the clinical setting and may contribute to future personalized
treatment [27] and may be important in epidemiological and transmission studies. Bioinfor‐
matics has played a major role in the development of various tools that can be used for
identifying genotypes/subgenotypes and detecting various mutations. Therefore, a number of
methods have been developed [28, 29].
Although analysis of the HBV S gene sequence is sufficient to classify HBV into genotypes [30],
the complete genome sequence provides additional information with respect to phylogenetic
relatedness [31, 32], including the identification of recombinants. Furthermore, even though
complete genome analysis is the gold standard for genotyping, it does not allow for rapid and
direct analysis on a large scale basis [17] and requires expertise and thus capacity development
in computer processing coupled with phylogenetic analyses. In order to expedite and facilitate
genotyping, a number of methods have been developed [17, 28, 29]. Each one has its advantages
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and disadvantages [17, 28, 29], which should be taken into account, when selecting the
genotyping method appropriate for a particular study or application.
2.8. Phylogenetic analyses of HBV
Although, as already mentioned, the error-prone polymerase of HBV leads to sequence
heterogeneity [16], the degree, at which this can occur, is constrained by the partially over‐
lapping ORFs and the presence of secondary RNA structures, such as ε, coded by non-
overlapping regions [33, 34]. The HBV genome has been estimated to evolve with an error rate
of ~10−3–10−6 nucleotide substitutions/site/year [35–41], although this rate is not constant within
the different regions of the HBV genome [41]. The progress of computers and information
technology has played an important role in the development of phylogenetic analysis as a
powerful tool in the analysis of the molecular evolution of viruses.
As exemplified in the next sections, comparative analysis of HBV strains from various
geographic regions of the world and from different eras can shed light on the origin, evolution,
transmission, and response to anti-HBV preventative and treatment measures.
2.9. Origin
The origin and age of the family Hepadnaviridae remains controversial. However, until the
issues with the estimation of the substitution rate of HBV [41] are overcome, the debate on the
origin of HBV will continue ([17, 41] and references cited therein). Nonetheless, bioinformatics,
coupled with growing number of hepadnaviral sequences in the databases, with accurate
sampling times, and advances in phylogenetic and coalescent methodology [42], is beginning
to shed light on this issue. For example, according to Suh and colleagues [43], analysis of the
endogenous sequences in the zebra finch provides direct evidence that the compact genomic
organization of hepadnaviruses has not changed during the last 482 million years of hepad‐
naviral evolution. Furthermore, phylogenetic analyses and distribution of HBV relics suggest
that birds potentially are the ancestral hosts of the family Hepadnaviridae and that mammalian
hepatitis B viruses probably emerged after a bird–mammal host switch [43].
2.10. Evolution
Genetic variation is important in viral evolution. The sequence heterogeneity displayed by
HBV because of the lack of proof-reading ability of the polymerase is limited by functional
constraints [33], leading to non-random variation [44]. Moreover, mutations can be affected
by host–virus interaction and selective pressure, imposed endogenously by the immune
system and exogenously by vaccination and antiviral treatment [17]. Phenotypic resistance to
antiviral drugs occurs because of mutations in the reverse transcriptase of POL, whereas
mutations in the BCP/preC and preS regions have been implicated as risk factors for the
development of HCC. Mutations in the S region coding for HBsAg can lead to both vaccine
and detection escape of HBV. At any time, the virus population can be composed of a number
of different mutants referred to as “quasispecies” [45]. Direct sequencing and more recently
next generation sequencing (NGS), parallel with bioinformatics, provide us with powerful
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tools to study the evolution of the various HBV mutations. NGS or ultra-deep sequencing
generates large volumes of data, which can only be analyzed using bioinformatics tools and
provides large coverage that can detect minor quasispecies populations of HBV [46–51] that
may be important in understanding HBV pathogenicity and response to treatment. In order
to minimize the number of artifactual calls of single-nucleotide variations in NGS, it is
important that the correct reference sequences are used [51, 52].
By designing a circular construct, Homs and co-workers [53] were able to use NGS to study
evolution of both the precore and polymerase regions. They demonstrated the presence of
precore mutants in HBeAg-positive phase, wild-type precore in the HBeAg-negative phase as
well as lamivudine resistance strains in treatment naïve patients. This demonstrates that viral
strains occurring at low frequencies can act as reservoirs or memory genomes, which are
selected and evolve in response to both intrinsic (host immune response) and extrinsic (drug
administration) factors.
2.11. Transmission and tracing human migrations
Sequencing and bioinformatics have played an important role in demonstrating transmission
routes, for which previous evidence could only be anecdotal. For example, molecular charac‐
terization of HBV together with phylogenetic analysis was used to demonstrate inter-spousal
transmission of HBV even after long marriages, in two Japanese patients, who developed acute
liver failure [54]. Similarly, the first known case of transfusion-transmitted HBV infection by
blood screened using individual donor nucleic acid testing was confirmed by the 99.7%
sequence homology between the complete genome sequences of the donor and the recipient
HBV strains [26]. When migration events were estimated by ancestral state reconstruction
using the criterion of parsimony, it was shown that Africa was the most probable source of
dispersal of subgenotype A1 of HBV globally and its dispersal to Asia and Latin America
occurred as a result of the slave and trade routes [23, 55].
2.12. Treatment response and resistance to treatment
According to international chronic hepatitis B treatment guidelines, the most desirable
endpoint of treatment is HBsAg loss. Following HBsAg loss, patients have better clinical
outcomes, including decreased risk of developing cirrhosis and HCC, and death [56]. How‐
ever, the currently available treatments, which include either nucleos(t)ide analogues (NAs)
for direct inhibition of the viral polymerase or pegylated interferon (PegIFN) for immune-
mediated HBV control, generally achieve HBV DNA suppression and HBeAg loss only, which
are not enduring. In an attempt to identify viral factors associated with HBsAg loss, Charuworn
et al. [57] demonstrated that viral diversity could differentiate those patients, who would lose
HBsAg when treated with tenofovir disoproxil fumarate. Lower diversity was seen in the
protein-encoding regions of HBV from patients who lost HBsAg compared to those who did
not. On the other hand, higher diversity in regulatory elements of HBV was found to be a
predictor of HBsAg loss [57]. These findings need to be confirmed by studies incorporating
larger numbers of patients, as well as genotypes other than A and D.
The Study of Hepatitis B Virus Using Bioinformatics
http://dx.doi.org/10.5772/63076
185
The high mutation rate of HBV means that it can evolve to develop resistance against NAs that
target the viral DNA polymerase. Drug-resistant mutants develop under drug pressure in
order for HBV to survive in the presence of the NA. The development of drug resistance
mutations can be affected by HBV DNA levels at baseline, rate of viral suppression, length of
NA treatment, and prior exposure to NA treatment [58]. Sequential treatment with different
NAs, following drug failure, can lead to the development of multidrug resistance, which
cannot be treated using currently available drugs [59]. The most frequent lamivudine drug
resistance mutants are rtM204V/I, which are also selected by the L-pyrimidine analogues,
emitricitabine, clevudine, and telbivudine but are susceptible to the purine analogues adefovir
and tenofovir [59]. rtA181V develops following lamivudine treatment but is sensitive to other
NAs, whereas rtN236T is resistant to adefovir only. In deciding on treatment options, the
detection of genotypic resistance, which is defined as the detection of viral mutations confer‐
ring drug resistance, is a priority in clinics. Direct and NGS of the polymerase region of the
HBV genome can detect both well-defined and novel mutations.
Bioinformatics tools and databases have been used to better understand HBV mutations and
how they develop, especially in response to antiviral therapy and vaccination. Although
laboratory methods have been used to study mutations, they are both labor intensive and
expensive and limited in the degree of complexity they can investigate. As a more economical
alternative, bioinformatics and computer simulation can use available biological data, such as
the protein sequence and structural information, to investigate interactions by virus, host, and
the environment [60]. Thus, Shen et al. [60] showed that most mutations develop in the
hydrophobic regions of HBsAg and POL and that the amino acids that are more likely to be
mutated are serine and threonine [60]. Understanding how amino acids mutations develop in
HBV proteins can facilitate the rational design of both vaccines and drugs [60], for the
prevention and treatment of HBV infection, respectively. By the use of bioinformatics to
compare viral and host genomic patterns, together with clinical information, to data from
databases can lead to enhanced and individualized antiviral therapy.
3. Bioinformatics tools and databases
3.1. Bioinformatics challenges of HBV
Despite its small genome size of ~3.2 kb, HBV presents several bioinformatic challenges:
1. The genome is circular, with position 1 conventionally taken to be the first “T” nucleotide
in the EcoR1 restriction site (“GAATTC”). Historically, position 1 was the start of the
“Core” region, which is position 1901 in the current numbering system. Therefore, a
number of sequences deposited earlier in the public databases are numbered using this
outdated system and thus require processing before they can be used in alignments,
together with more recently submitted sequences.
2. Four overlapping reading frames are encoded in the circular genome, whereas nucleotides
or amino acids are sequenced and processed linearly. Extracting nucleotide or amino acid
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sequences for the S and POL ORFs, which span the EcoRI site, from full-length or subge‐
nomic fragments, requires additional processing.
3. The differences in genome lengths between the nine HBV genotypes (ranging from 3182
to 3248 base pairs in length) mean that direct comparison of loci between genotypes is not
always possible using the current numbering system. These differences in genome lengths
result in genotype alignments containing several regions of gaps, ranging from 3 to 33
nucleotides in length. A possible solution is the implementation of a standardized
“universal numbering system” for all HBV genotypes, which we are currently developing.
4. Sequence variability is a feature of HBV. It is, therefore, essential to check all sequences
carefully, to distinguish between artifacts and true variation (mutations). Variation within
a population at a locus may result in two overlapping peaks on a chromatogram. Super-
infections or co-infections with different strains may result in mixed populations, which
appear as multiple or misaligned peaks on sequencing chromatograms. Disambiguating
these is essential for robust downstream analyses.
3.2. Public sequence databases
The first public sequence database, “GenBank,” was established in 1982, having arisen from
the earlier Los Alamos database, established in 1979 [61, 62]. Since then, the number of
nucleotides in GenBank has doubled approximately every 18 months [63]. The International
Nucleotide Sequence Database Collaboration (INSDC) is a collection of three publicly available
nucleotide (DNA or RNA) sequence databases, which synchronize data daily [64]. The
collection consists of the DNA DataBank of Japan (DDBJ, located in Japan), the European
Molecular Biology Laboratory (EMBL, located in the United Kingdom) and GenBank (located
in the United States of America). The latest release of the database (release 211.0, from 15
December, 2015; [65]) contains 189,232,925 loci and 203,939,111,071 bases, from 189,232,925
sequences, totaling approximately 742 gigabytes. In addition to the INSDC, many other
databases exist, including genome databases, protein sequence, structure and interaction
databases, microarray databases, and meta-databases. A list of biological databases on
Wikipedia includes over 200 entries [66].
When searching for “hepatitis b virus” across all fields, the GenBank database [63], accessed
on 27th January 2016, contained 105,745 sequences. When searching for “hepatitis b virus” in
the “organism” field only, 84,119 sequences were found, with the oldest sequence submitted
in the early 1980s. Refining this search to include only sequences of 200 nucleotides or longer,
and excluding words such as “recombinant,” “clone,” and “patent,” resulted in 68,762
sequences. When this same query was previously executed on 29 November 2015, 67,893
sequences were returned. Therefore, in the 59 days between the two queries, 869 new sequen‐
ces (of at least 200 nucleotides in length, and not containing the words mentioned previously)
were uploaded to GenBank. On average, this equates to almost 15 new HBV sequences added
to GenBank per day.
Making use of these sequences in downstream applications, such as multiple sequence
alignments or phylogenetic analyses, is often challenging, as it is difficult to query for sufficient
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sequences, of the correct genotype, or subgenotype, and covering the required genomic region.
In order to overcome this limitation, we have developed a bioinformatics solution, whereby
all sequences matching a query are downloaded, curated, and aligned. The algorithm
developed allows for the generation of a multiple sequence alignment for each genotype,
which contains all the available sequences matching the query and in their correct position
and orientation [67].
3.3. Bioinformatics tools for HBV
Workflow Tool name and description
Chromatograms Quality score analyzer
• Plots chromatogram quality scores
Automatic contig generator tool
• Generates a contig from a forward and reverse chromatogram
Alignment Automatic alignment clean-up tool
• Eliminates “gap-columns” and disambiguate ambiguous bases
Mind the gap
• Splits FASTA file based on gap threshold per column
Analysis Babylon
• Extracts HBV protein sequences (ORFs)
Wild-type 2 × 2
• Calculates 2 × 2 wild-type/mutant contingency tables
Divergence calculator*
• Intra- and Inter-group divergence with custom groups
Rafael*
• Generates random subsets from an input FASTA file
Serotyping HBV serotyper tool
• Determines HBV serotype
Phylogenetics Pipeline: TreeMail
• Generates a phylogenetic tree
GenBank Submission PadSeq
• Places two HBV sequence fragments on a backbone template
¶Table modified from Bell and Kramvis [68].
*Described for the first time here.
Table 2. List of the online tools developed and the workflow process at which each would be used¶.
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A standard molecular biology laboratory workflow includes DNA extraction, polymerase
chain reaction (PCR) amplification, direct DNA sequencing, viewing and checking of
chromatograms, preparation of curated sequences, multiple sequence alignment, sequence
analysis, serotyping, genotyping, phylogenetic analysis, and preparation of sequences for
submission to the GenBank public sequence database [68]. Each of these steps presents data
processing challenges, many of which have been addressed by the development of a suite of
online tools (Table 2) [68].
Name URL Usage References
Geno2Pheno [hbv] http://www.genafor.org/g2p_hbv/index.php Drug resistance mutations,
escape mutant analysis
[69]
HBV Blast Search http://www.bioafrica.net/blast/hbvblast.html Genotyping, drug resistance
database
[70]
HBV STAR http://www.vgb.ucl.ac.uk/starn.shtml Genotyping [71]
HBVRegDB http://lancelot.otago.ac.nz/HBVRegDB/ Annotation, alignments,
information about conserved
regions
[72]
HBVdb http://hbvdb.ibcp.fr/ Genotyping, annotation, drug
resistance database
[73]
HBVseq http://hivdb.stanford.edu/HBV/HBVseq/
development/HBVseq.html
Hepatitis virus database http://s2as02.genes.nig.ac.jp/ Genotyping, sequence
alignment and map viewing
Hepatitis virus database http://www.ibibiobase.com/projects/hepatitis/
index.htm
NCBI genotyping tool http://www.ncbi.nlm.nih.gov/projects/
genotyping/
Genotyping [74]
Oxford HBV subtyping
tool
http://www.bioafrica.net/rega-genotype/html/
subtypinghbv.html
Genotyping [70]
RegaDB http://regaweb.med.kuleuven.be/software/regadb
SeqHepB http://www.seqhepb.com/ Sequence analysis, genotyping,
detection of clinically
important mutations
[75]
¶Table modified from [67].
Table 3. Currently available HBV websites and databases¶.
Any operating system platform from any location with an internet connection can be used to
access stand-alone, web-based tools. There is no requirement to install and learn new bioin‐
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formatics software, as these tools can be used when required. A system for processing ultra-
deep pyrosequencing (amplicon resequencing) data has also been developed [51]. In addition,
a number of HBV-specific websites and databases are currently available, a selection of which
are represented in Table 3.
3.4. New bioinformatics tools for HBV
Here, we present two newly developed tools for the bioinformatic analysis of HBV.
3.4.1. Divergence calculator [http://hvdr.bioinf.wits.ac.za/divergence/]
One method of classifying HBV sequences into genotype or subgenotype is to examine
nucleotide sequence divergence between sequences. This divergence calculation is performed
by totaling the number of nucleotides, which differ, between two aligned sequences and
computing the percentage difference. The divergence calculator (Figure 3) performs various
divergence calculations on groups of sequences from nucleotide or amino acid multiple
sequence alignments in FASTA format. A minimum of one group containing two sequences,
or two groups containing one sequence each, must be specified.
Figure 3. The input screen of the divergence calculator in which sequences are extracted and allocated to groups and
other parameters specified.
As an example, consider an alignment of 10 genotype A sequences (group 1) and 10 genotype
D sequences (group 2). Intra-group divergence, for each group, is calculated by comparing
each sequence in group 1 with each other sequence in group 1 and then calculating the median,
mean, and standard deviation of the divergences. This is then repeated for group 2. The inter-
group divergence compares each sequence in group 1 with each sequence in group 2, and then
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calculates the median, mean, and standard deviation. If more than two groups are specified,
the calculations iterate over all groups in turn.
If the optional “query” group is specified, the tool compares each sequence in the query group
with each sequence in the other group or groups, but outputs statistics for each sequence in
the query group individually. This method would typically be used with a set of unknown
query sequences and one or more groups of reference sequences. A comprehensive list of
descriptive statistics is included on the output page for each analysis.
3.4.2. Random FASTA extraction and allocation (RAFAEL) [http://hvdr.bioinf.wits.ac.za/rafael/]
In some analyses, particularly when constructing phylogenetic trees, it may be desirable to
extract one or more random subsets of sequences from a master or reference alignment. The
“RAFAEL” tool was designed to perform this task. This tool takes an input file in FASTA
format, which does not have to be aligned and generates one or more subsets of the file, each
containing a random selection of the specified number of sequences. The number of sequences
may be specified as a count, or as a percentage of the number of sequences in the input file.
There are guaranteed to be no duplicate sequences within each subset. However, duplicates
may exist in multiple subsets, as subsets are not unique.
3.5. Open-source software
In addition to biological databases, a large variety of biological analysis software, which is
generally genome agnostic, is available. As with software in any field, the licensing terms and
commercial costs of these packages vary widely. Packages, which may be free of cost, may not
necessarily be open-source, for example.
The Free Software Foundation (FSF) [76, 77] defines free software as software which “respects
the users’ freedom” in the sense that “users have the freedom to run, copy, distribute, study,
change, and improve the software”. As such, “free” is “a matter of liberty, not price”. Free
software, therefore, does not necessarily have to be made available at no cost or be a non-
commercial project. Furthermore, software, which is provided at no cost, may not be “free” in
the sense described above.
The term “open-source” is often used when referring to “free” software. However, the two
terms are not synonymous, although there is some overlap. Open-source software may, or may
not, be free software, depending on the restrictions placed on users by the software. If the user
is not free to distribute, change, and improve the software, even if it is open source, then it
cannot be considered to be free software. Most software, for which a license is purchased, is
not free, or open source. The user does not have the freedom to distribute the software, or to
use it on any computer chosen.
3.6. Recommended software
A list of recommended freely available download software is presented in Table 4. Compre‐
hensive lists of open-source bioinformatics software can be found elsewhere [78].
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Software
name 
Software
description
Website (http://) Lin* Mac* Win* References
Unipro UGene Integrated bioinformatics
suite  
ugene.net Yes Yes Yes [79]
MEGA 6 Integrated bioinformatics
suite; command-line version
available
megasoftware.net Emu Yes Yes [80]
BioEdit Multiple sequence
alignment viewer and editor
www.mbio.ncsu.edu/bioedit/
bioedit.html
No No Yes
SeaView Multiple sequence
alignment viewer and
editor, and molecular
phylogenetics; opens
GeneDoc “MSF” files
doua.prabi.fr/software/seaview Yes Yes Yes [81]
AliView Multiple sequence
alignment viewer and editor
www.ormbunkar.se/aliview Yes Yes Yes [82]
GeneDoc Multiple sequence
alignment viewer and
editor, and shading utility
iubio.bio.indiana.edu/soft/molbio/
ibmpc/genedoc-readme.html
No No Yes
PHYLIP Programs for interring
phylogenies; website
includes comprehensive list
of other phylogenetics
programs
evolution.genetics.washington.edu/
phylip.html
Yes Yes Yes [83]
MrBayes Bayesian inference and
model choice using Markov
Chain Monte Carlo
mrbayes.sourceforge.net Com Yes Yes [84]
BEAST Bayesian analysis of
molecular sequences using
Markov Chain Monte Carlo
beast.bio.ed.ac.uk Yes Yes Yes [85]
FigTree Graphical viewer and editor
of phylogenetic trees
tree.bio.ed.ac.uk/software/figtree/ Yes Yes Yes
Archaeopteryx Graphical viewer and editor
of phylogenetic trees
sites.google.com/site/cmzmasek/home/
software/archaeopteryx
Yes No Yes [86]
EMBOSS A suite of command-line
tools for molecular biology
emboss.sourceforge.net/ Yes Yes Emu
JalView Multiple sequence
alignment viewer and editor
www.jalview.org Yes Yes Yes [87]
Finch TV DNA sequence trace
(chromatogram) viewer
www.geospiza.com/Products/
finchtv.shtml
Yes Yes Yes
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Software
name 
Software
description
Website (http://) Lin* Mac* Win* References
Chromas DNA sequence trace
(chromatogram) viewer
technelysium.com.au/?page_id=13 No No Yes
*“GUI” = graphical user interface, “CL” = command line interface, “OSS” = open-source software, “Lin” = GNU/Linux,
“Mac” = Apple MacIntosh, “Win” = Microsoft Windows, “Emu” = emulator or virtual machine recommended by
authors, “Com” = compilation from source code required.
Table 4. Bioinformatics software available free of charge for various computer operating system platforms.
4. Conclusion
The unique genome structure and molecular biology of HBV pose a number of challenges, and
thus, the development of bioinformatic tools has facilitated a more comprehensive and detailed
analysis and understanding of the origin, evolution, transmission, and response to antiviral
agents of HBV and its interaction with the host. There are a wide range of free and commercially
available tools, which have been developed for different applications. The availability and
applications of high-throughput sequencing techniques and the advancement of “-omics” will
continue to provide additional challenges, which will need to be addressed by further
computational solutions.
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